0.8921
price up icon0.24%   0.0021
after-market Dopo l'orario di chiusura: .90 0.0079 +0.89%
loading
Precedente Chiudi:
$0.89
Aprire:
$0.92
Volume 24 ore:
127.80K
Relative Volume:
0.10
Capitalizzazione di mercato:
$12.61M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.0583
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
-8.03%
1M Prestazione:
-9.58%
6M Prestazione:
-66.84%
1 anno Prestazione:
-80.52%
Intervallo 1D:
Value
$0.87
$0.92
Intervallo di 1 settimana:
Value
$0.86
$0.9681
Portata 52W:
Value
$0.3975
$4.90

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
Nome
Moleculin Biotech Inc
Name
Telefono
713-300-5160
Name
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
Dipendente
17
Name
Cinguettio
@moleculinbio
Name
Prossima data di guadagno
2024-12-08
Name
Ultimi documenti SEC
Name
MBRX's Discussions on Twitter

Confronta MBRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MBRX
Moleculin Biotech Inc
0.8921 13.70M 0 -29.77M -24.23M -15.30
Biotechnology icon
ONC
Beigene Ltd Adr
240.41 25.57B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.10 111.79B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 39.90M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
591.85 65.28B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.93 6.31B 0 -153.72M -103.81M -2.00

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-12 Downgrade Maxim Group Buy → Hold
2022-07-18 Ripresa Oppenheimer Outperform

Moleculin Biotech Inc Borsa (MBRX) Ultime notizie

pulisher
May 23, 2025

Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks

May 23, 2025
pulisher
May 23, 2025

Moleculin receives Nasdaq non-compliance notice - Investing.com

May 23, 2025
pulisher
May 19, 2025

Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN

May 19, 2025
pulisher
May 17, 2025

Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World

May 17, 2025
pulisher
May 16, 2025

Moleculin Biotech reaches agreement to amend investor warrants - MSN

May 16, 2025
pulisher
May 16, 2025

MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN

May 16, 2025
pulisher
May 16, 2025

Moleculin Announces First European Approval for Phase 3 AML Trial - MSN

May 16, 2025
pulisher
May 15, 2025

Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks

May 15, 2025
pulisher
May 15, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Moleculin Biotech Reports Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup - MSN

May 14, 2025
pulisher
May 14, 2025

Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Moleculin Biotech reports Q1 2025 updates By Investing.com - Investing.com India

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Moleculin Biotech reports Q1 2025 updates - Investing.com

May 14, 2025
pulisher
May 14, 2025

Moleculin Reports First Quarter 2025 Financial Results and Provi - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Prog - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Progress | MBRX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Moleculin Biotech reports Q1 EPS (69c) vs ($2.02) last year - TipRanks

May 14, 2025
pulisher
May 14, 2025

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Moleculin's AML Treatment Trial Gets Major EU Expansion as Q1 Results Reveal Timeline for Critical Data - Stock Titan

May 14, 2025
pulisher
May 13, 2025

MOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly Earnings - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Moleculin Biotech, Inc. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

EMA approves Moleculin’s application for Phase IIb/III AML trial - Yahoo

May 13, 2025
pulisher
May 12, 2025

Moleculin expands EU trial for leukemia treatment By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

Moleculin Biotech (MBRX) Gains EMA Approval for Pivotal Phase 2B/3 AML Trial | MBRX Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Moleculin Receives European Medicines Agency Approval to Expand - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Moleculin expands EU trial for leukemia treatment - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Moleculin Receives European Medicines Agency Approval To Expand Phase 3 Miracle Clinical Trial - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Moleculin Biotech’s Annamycin Trial Approved by EMA - TipRanks

May 12, 2025
pulisher
May 12, 2025

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial - The Manila Times

May 12, 2025
pulisher
May 12, 2025

Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

May 12, 2025
pulisher
May 10, 2025

Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum By Investing.com - Investing.com India

May 10, 2025
pulisher
May 10, 2025

Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum - Investing.com Australia

May 10, 2025
pulisher
May 09, 2025

Moleculin Biotech Cancels Special Stockholders Meeting - TipRanks

May 09, 2025
pulisher
May 09, 2025

Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow

May 09, 2025
pulisher
May 07, 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - Seeking Alpha

May 07, 2025
pulisher
May 07, 2025

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - Seeking Alpha

May 07, 2025
pulisher
May 07, 2025

Moleculin Biotech to Announce Q1 2025 Financial Results - TipRanks

May 07, 2025
pulisher
May 07, 2025

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Moleculin Biotech Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView

May 06, 2025
pulisher
May 06, 2025

Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non- - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non-proprietary Name | MBRX Stock News - GuruFocus

May 06, 2025

Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.05
price down icon 8.70%
$30.28
price down icon 2.39%
$576.24
price down icon 0.61%
$285.56
price down icon 1.56%
$4.35
price up icon 1.64%
$73.93
price down icon 2.22%
Capitalizzazione:     |  Volume (24 ore):